Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: A randomized double-blind placebo-controlled multicenter clinical study.

Autor: Zhu H; Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center of Kidney Diseases, Beijing Key Laboratory of Kidney Disease, Beijing, China., Chen X; Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center of Kidney Diseases, Beijing Key Laboratory of Kidney Disease, Beijing, China., Cai G; Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center of Kidney Diseases, Beijing Key Laboratory of Kidney Disease, Beijing, China., Zheng Y; Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center of Kidney Diseases, Beijing Key Laboratory of Kidney Disease, Beijing, China., Liu M; Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center of Kidney Diseases, Beijing Key Laboratory of Kidney Disease, Beijing, China., Liu W; Department of Nephrology, Beijing Friendship Hospital, Capital Medical University, Beijing, China., Yao H; Department of Endocrinology, Navy General Hospital, Beijing, China., Wang Y; Department of Nephrology, General Hospital of Beijing Military Command, Beijing, China., Li W; Department of Nephrology, China-Japan Friendship Hospital, Beijing, China., Wu H; Department of Nephrology, Beijing Hospital, Beijing, China., Lun L; Department of Nephrology, Air Force General Hospital, Beijing, China., Zhang J; Department of Nephrology, General Hospital of Chinese People's Armed Police Forces, Beijing, China., Guan X; Department of Endocrinology, Air Force General Hospital, Beijing, China., Yin S; Department of Endocrinology, First Affiliated Hospital of the General Hospital of Chinese People's Liberation Army, Beijing, China., Zhuang X; Department of Endocrinology, Fuxing Hospital, Capital Medical University, Beijing, China., Li J; Department of Nephrology, First Affiliated Hospital of the General Hospital of Chinese People's Liberation Army, Beijing, China., Liu Y; Department of Endocrinology, 306th Hospital of Chinese People's Liberation Army, Beijing, China., Zhou C; Department of Nephrology, Navy General Hospital, Beijing, China.
Jazyk: angličtina
Zdroj: Journal of diabetes [J Diabetes] 2016 Sep; Vol. 8 (5), pp. 677-85. Date of Electronic Publication: 2015 Dec 29.
DOI: 10.1111/1753-0407.12347
Abstrakt: Background: Persistent proteinuria is an important factor contributing to the progression of diabetic nephropathy. The present randomized double-blind placebo-controlled multicenter clinical study evaluated the efficacy and safety of telmisartan combined with the antioxidant probucol in reducing urinary protein levels in patients with type 2 diabetes (T2D).
Methods: Patients with T2D and 24-h proteinuria 0.5-3 g were enrolled in the study and randomly assigned to one of two groups: a telmisartan or a probucol + telmisartan group. Both groups were given telmisartan 80 mg q.d. for 48 weeks. The probucol + telmisartan group was given probucol 500 mg b.i.d. for the first 24 weeks, with the dosage then reduced to 250 mg b.i.d. for the remaining 24 weeks. The telmisartan group was given probucol placebo.
Results: In all, 160 patients were enrolled in the present study. The 24-h proteinuria levels were significantly reduced in the probucol + telmisartan compared with telmisartan group. For patients with baseline 24-h proteinuria levels <1.0 g, both treatments resulted in significant reductions in 24-h proteinuria levels after 48 weeks treatment. However, in patients with baseline 24-h proteinuria levels ≥1.0 g, 24-h proteinuria levels after 48 weeks treatment were only reduced in the probucol + telmisartan group. There was no significant difference between the two groups for either adverse cardiovascular or other events.
Conclusions: In patients with diabetic nephropathy, probucol combined with telmisartan more effectively reduces urinary protein levels than telmisartan alone.
(© 2015 The Authors. Journal of Diabetes published by Wiley Publishing Asia Pty Ltd and Ruijin Hospital, Shanghai Jiaotong University School of Medicine.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje